1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Personalis, Inc.
  6. Company
    PSNL   US71535D1063

PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Personalis, Inc.
Personalis, Inc. is a cancer genomics company, which enables precision cancer therapies and diagnostics. The Company is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. It provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. It also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Number of employees : 326 people.
Sales per Business
20202021Delta
United States Veterans Affair's Million Veteran Program56.1571.4%45.6753.4% -18.67%
All Other Customers22.4928.6%39.8246.6% +77.04%
USD in Million
Sales per region
20202021Delta
United States74.7295%78.6592% +5.27%
International3.935%6.848% +73.93%
USD in Million
Managers
Name Title Age Since
John S. West President, Chief Executive Officer & Director 64 2011
Aaron Tachibana Chief Financial Officer & Senior Vice President 60 2019
Richard O. Chen, Dr. Chief Medical Officer, SVP-Research & Development 50 2021
Xavier Paliard, Dr. Vice President-Immunology, Research & Development - 2017
Carol J. Tillis Vice President-Finance & Administration - 2011
Caroline Corner Investor Relations Contact - -
James Azzaro Vice President-Diagnostic Sales - 2022
Christian D. Haudenschild, Dr. Vice President-Genomic Services - 2012
Leslie Grab, Dr. Vice President-Intellectual Property - 2020
John Lyle, Dr. Vice President-Assay Research & Development - 2020
Members of the board
Name Title Age Since
Jonathan J. MacQuitty, Dr. Chairman 68 -
Kenneth E. Ludlum Independent Director 67 2015
Arthur Blaine Bowman Independent Director 74 2019
Alan B. Colowick, Dr. Independent Director 59 2019
Karin Eastham Independent Director 71 2019
Woodrow A. Myers, Dr. Independent Director 67 2021
Olivia K. Bloom Director 52 2022
John S. West President, Chief Executive Officer & Director 64 2011
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 45,446,930 44,497,761 97.9% 0 0.0% 97.9%
Shareholders
NameEquities%
Lightspeed Management Co. LLC 8,165,484 18.1%
ARK Investment Management LLC 5,184,784 11.5%
Abingworth LLP 4,462,452 9.88%
JPMorgan Investment Management, Inc. 2,998,883 6.64%
The Vanguard Group, Inc. 2,019,280 4.47%
BlackRock Fund Advisors 1,507,911 3.34%
Millennium Management LLC 1,350,852 2.99%
Swedbank Robur Fonder AB 1,197,000 2.65%
JPMorgan Asset Management (UK) Ltd. 1,157,588 2.56%
Nikko Asset Management Americas, Inc. 1,001,424 2.22%
Company contact information
Personalis, Inc.
1330 O'Brien Drive
Menlo Park, CA 94025

Phone : +1.650.752.1300
Fax : +1.650.752.1301
Web : http://www.personalis.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Personalis, Inc.